Multiple Myeloma

Talquetamab Cost-Effective Breakthrough for RRMM

May 15th 2024

Janssen image | Image Credit: Sundry Protography - stock.adobe.com

Study Urges Personalized Care to Boost Quality of Life in Patients With MM

April 23rd 2024

Open book on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com.

FDA Approves Cilta-Cel for Earlier Treatment of RRMM

April 11th 2024

FDA approval indication | Image Credit: Dzmitry - stock.adobe.com

1.0 Credits / Hematologic Cancer, Oncology

April 6th 2024

Continuing Medical Education

May 29th 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

May 29th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

May 29th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Continuing Medical Education

View All

On-Demand Webinar

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology

On-Demand Virtual Symposium

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

On-Demand Virtual Symposium

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

August 27th 2022

Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years

Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

August 19th 2022

Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care

Maggie L. Shaw

This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).

August 12th 2022

QOL Tool Valuable in Identifying Patients’ Chief Concerns

Julia Bonavitacola

A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.

August 10th 2022

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.

August 6th 2022

Rare MM Case Underscores Need to Consider Differential Diagnoses

Maggie L. Shaw

In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.

August 4th 2022

NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression

Maggie L. Shaw

Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.

July 28th 2022

Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment

Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.

July 18th 2022

With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients

A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.

July 16th 2022

Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma

Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.

July 12th 2022

Age, Infection, Cardiac Disease Linked to Early Death for Patients With Newly Diagnosed Multiple Myeloma

Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.

July 9th 2022

Index Finds Half of MM, CLL Patients in Study Had Financial Difficulty

Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.

July 2nd 2022

Review of MM Treatment Landscape Compares Clinical Trials With Real-World Results

Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.

July 1st 2022

Exploring Genomic and Transcriptomic Changes Throughout Multiple Myeloma Progression

Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.

June 28th 2022

Discussing The Future of the RRMM Treatment Landscape

Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.

June 28th 2022

Improving Payer Education on RRMM Therapy

Professional experts offer suggestions on how payers can be further educated on RRMM treatment.

June 28th 2022

How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.

June 25th 2022

Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM

Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).

June 21st 2022

Ways Institutions Can Support RRMM Treatment Selection

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

June 21st 2022

Using Lenalidomide and Pomalidomide in RRMM Management

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

June 19th 2022

Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma

Lindsey Mulrooney

Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.

June 18th 2022

Review Highlights Nanomedicine as Potential Drug Delivery Strategy in Multiple Myeloma

A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine.

June 15th 2022

Vitamin D Provides Therapeutic Benefit Among Patients With MM, Review Says

Skylar Jeremias

A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.

June 14th 2022

Preferred IMiDs Regimens Based on Line of Therapy

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

June 14th 2022

What Factors Into IMiDs Treatment Selection for Patients With RRMM?

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

June 7th 2022

IMiDs and Triplet Regimens in MM and RRMM Therapy

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.

June 7th 2022

RRMM: An Overview

Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).

June 4th 2022

High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study

As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.

June 3rd 2022

Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM

The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.

May 28th 2022

Is There a Possibility of a Cure in Multiple Myeloma?

Multiple myeloma has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease.

May 27th 2022

Myelofibrosis May Predict Extramedullary Disease in MM